Pneumotox » Drug » Nonsteroidal anti-inflammatory drugs (NSAIDs)

Nonsteroidal anti-inflammatory drugs (NSAIDs)

5

Risks depends on COX-selectivity. Review and guidelines at PMID 21631520. Studies on selective rechallenge at PMID 21981353 and 23278883

Last update : 23/09/2018

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

3

I.e Acute eosinophilic pneumonia (AEP)

1

II.a Pulmonary edema, noncardiogenic (NCPE)

1

IV.a Bronchospasm - Wheezing - Asthma

4

IV.f Severe or catastrophic bronchospasm or asthma attack (can be fatal)

3

V.q Empyema

1

VII.a Lymphadenopathy (intrathoracic)

1

VIII.a Angioedema (may cause UAO, asphyxia and death)

2

VIII.y Sinonasal discharge, -blockage, -obstruction

4

IX.f Hiccup

1

X.a DRES syndrome - DRESS-like reaction

1

X.b Antiphospholipid antibodies w/wo the APL syndrome

1

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

5

X.g Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

4

XI.b Chest pain (acute or subacute), lone or prominent

1

XIV.a Methemoglobinemia

1

Diagnosing DIRD

1

Drug and radiation history

2

Drug singularity - Correct identification of the drug

3

Consistent timing of exposure v. onset of symptoms

4

Clinical, imaging, BAL, pathological pattern consistent with the specific drug

5

Careful exlusion of another cause

6

Remission of symptoms with removal of drug

7

Recurrence with rechallenge (rarely advisable)

8

Causality assessment

More detailed checklist